Document:

Fourth Amendment to First Amended and Restated 2004 Incentive Award Plan

 Exhibit 10.1 
 FOURTH AMENDMENT TO 
 FIRST AMENDED AND RESTATED 

DIGITAL REALTY TRUST, INC., DIGITAL SERVICES, INC. AND 
 DIGITAL REALTY TRUST, L.P. 2004 INCENTIVE AWARD PLAN 
 THIS FOURTH
AMENDMENT TO THE FIRST AMENDED AND RESTATED DIGITAL REALTY TRUST, INC., DIGITAL SERVICES, INC. AND DIGITAL REALTY TRUST, L.P. 2004 INCENTIVE AWARD PLAN, made as of April 23, 2012 (this “Fourth Amendment”), is made and adopted
by Digital Realty Trust, Inc., a Maryland corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Plan (as defined below). 

WHEREAS, the Company maintains the First Amended and Restated Digital Realty Trust, Inc., Digital Services, Inc. and Digital Realty
Trust, L.P. 2004 Incentive Award Plan, as amended by the First, Second and Third Amendments thereto (the “Plan”); 
 WHEREAS, pursuant to Section 14.1 of the Plan, the Plan may be amended from time to time by the Company’s Board of Directors (the “Board”); and 

WHEREAS, the Company desires to amend the Plan as set forth herein. 

NOW, THEREFORE, BE IT RESOLVED, that the Plan be amended as follows: 

1. Subsections 8.10(a) and 8.10(b) of the Plan are hereby amended and restated in their entirety as follows: 

“8.10 Granting of Profits Interest Units to Independent Directors. 

(a) Pro Rata Grant. During the term of the Plan, commencing after the Company’s 2012 annual meeting of
stockholders (the “2012 Annual Meeting”), each person who first becomes an Independent Director on a date other than the date of an annual meeting of the Company’s stockholders shall, on the date of such person first becoming
an Independent Director, be granted a number of Profits Interest Units equal to the product of (A) the quotient obtained by dividing (x) $100,000 by (y) the Fair Market Value of a share of Stock on such date, multiplied by
(B) the quotient obtained by dividing (x) 12 minus the number of months that have elapsed since the immediately preceding annual meeting of the Company’s stockholders, by (y) 12 (the “Pro Rata Grant”).

 (b) Annual Grant. During the term of the Plan, commencing as of the 2012 Annual Meeting, each person
who first becomes an Independent Director at such annual meeting and each person who otherwise continues to be an Independent Director immediately following such annual meeting shall, on the date of each such annual meeting, be granted a number of
Profits Interest Units equal to the quotient obtained by dividing (x) $100,000 by (y) the Fair Market Value of a share of Stock on the date of such annual meeting (the “Annual Grant”).” 

 2. Subsection 8.10(c) of the Plan is hereby amended by deleting the phrase “Fifth
Annual Meeting” from the first sentence of such subsection and replacing it with the phrase “fifth annual meeting of the Company’s stockholders following the Public Trading Date.” 

3. This Fourth Amendment shall be and is hereby incorporated in and forms a part of the Plan. 

4. All other terms and provisions of the Plan shall remain unchanged except as specifically modified herein. 

[SIGNATURE PAGE FOLLOWS] 

 I hereby certify that the foregoing Fourth Amendment was duly adopted by the Board of Directors of Digital
Realty Trust, Inc. on April 23, 2012. 
 Executed on this 23rd day of April, 2012. 

 

	
	 /s/ Joshua A. Mills

	Assistant SecretaryDirector Compensation Program

 Exhibit 10.2 
 Director Compensation Program 
 On April 23, 2012, the Board of
Directors of Digital Realty Trust, Inc. (the “Company”) approved amendments to the Company’s director compensation, effective April 23, 2012, as follows: 
 Each of the Company’s directors who is not an employee of the Company or any of its subsidiaries receives an annual cash retainer of $60,000 for services as a director. Directors receive annual fees
for service on the following committees, in addition to the foregoing retainer of $60,000: $10,000 for Audit Committee, $7,500 for Compensation Committee and $7,500 for Nominating and Corporate Governance Committee. The director who serves as the
chair of the Audit Committee receives an additional annual retainer of $20,000; the director who serves as the chair of the Compensation Committee receives an additional annual retainer of $15,000; and the director who serves as the chair of the
Nominating and Corporate Governance Committee receives an additional annual retainer of $15,000. In addition, any non-employee director who serves as Chairman of the Board receives an annual cash retainer of $25,000 (in addition to the annual cash
base retainer of $60,000). 
 The Company’s Incentive Award Plan provides for formula grants of long-term incentive units
to non-employee directors as follows: 
  

	 	•	 	 Pro Rata Grant. Commencing after the 2012 Annual Meeting of Stockholders, each person who first becomes a non-employee director on a date other
than the date of an annual meeting of stockholders will, on the date of such person first becoming a non-employee director, be granted a number of long-term incentive units equal to the product of (A) the quotient obtained by dividing
(x) $100,000 by (y) the fair market value of a share of Common Stock on such date, multiplied by (B) the quotient obtained by dividing (x) 12 minus the number of months that have elapsed since the immediately preceding annual
meeting of stockholders, by (y) 12. The award will be fully vested on the date of grant. 

  

	 	•	 	 Annual Grant. Commencing as of the 2012 Annual Meeting of Stockholders, each person who first becomes a non-employee director at an annual
meeting of stockholders and each person who otherwise continues to be a non-employee director immediately following such annual meeting will, on the date of such annual meeting, be granted a number of long-term incentive units equal to the quotient
obtained by dividing (x) $100,000 by (y) the fair market value of a share of Common Stock on the date of such annual meeting. The award will be fully vested on the date of grant.Consulting and Scientific Advisory Board Agreement

 Exhibit 10.1 
 Consulting and Scientific Advisory Board Agreement 
 This Consulting
and Scientific Advisory Board Agreement (the “Agreement”), shall be effective as of January 1, 2012 (the “Effective Date”), and is entered into by AVEO Pharmaceuticals, Inc., a Delaware corporation with a business address at
75 Sidney Street, Cambridge, MA 02139 (the “Company”), and Lynda Chin, MD of 2421 Inwood, Houston, Texas 77019 (the “Advisor”). 
 Witnesseth 
 Whereas, the Advisor is an employee of The University
of Texas MD Anderson Cancer Center (the “Advisor’s Employer”). 
 Whereas, the Company desires to have the
benefit of the Advisor’s knowledge and experience in the development of its technology base, and the Advisor desires to provide consulting services to the Company, all as hereinafter provide in this agreement; and 

Whereas the Company desires to have the Advisor continue to serve as a member of the Company’s Scientific Advisory Board (the
“SAB”), and the Advisor desires to serve as a member of the SAB; 
 Now, Therefore, in consideration of the promises
and mutual agreements hereinafter set forth, effective the date hereof, the Company and the Advisor hereby agree as follows: 

1. Consultation and Scientific Advisory Board The Company shall retain the Advisor as a consultant, and the Advisor shall serve
the Company as a consultant and a member of the SAB upon the terms and conditions hereinafter set forth. In serving the Company as a consultant and member of the SAB, the Advisor is acting in her individual capacity and not as an employee or
representative of the Advisor’s Employer. 
 2. Term. Subject to the terms and conditions hereinafter set forth, the
term of the Advisor’s consulting arrangement and service on the SAB (hereinafter referred to as the “Consultation Period”) shall commence on the Effective Date of this agreement and shall continue through December 31, 2013,
subject to earlier termination as provided herein. This Agreement may be renewed by mutual consent of both parties. 
 3.
Consulting and Board Member Duties 
 3.1 During the Consultation Period, the Advisor shall serve as a member of the SAB
and shall render to the Company or to the Company’s designee such consulting services in the Advisor’s field of expertise and knowledge related to the technologies and business of the Company (the “Services”) and at such times
and places as the Company may from time to time request. The Company shall give the Advisor reasonable advance notice of any consulting services required of the Advisor hereunder. 

3.2 All work to be performed by the Advisor for the Company shall be under the general supervision of the Company. 

 3.3. The Advisor shall devote her reasonable best efforts and ability to the performance of
the duties attached to this obligation. All work to be performed by the Advisor for the Company shall be at times reasonably convenient to the Advisor, and nothing contained herein shall interfere with the Advisor’s duties and responsibilities
to the Advisor’s Employer, or any teaching and administrative responsibilities that the Advisor may have. In order to assure that Advisor’s service to the Company does not interfere with Advisor’s obligations and duties to the
Advisor’s Employer, the maximum number of days per fiscal year (September 1-August 31) that Advisor will be required to serve the Company as a consultant and a member of the SAB is 12 days (including travel days). 

3.4 In order to assure that Advisor has sufficient time to devote to her services under this Agreement and that other consulting services
do not conflict with her services to the Company hereunder, Advisor will not undertake consulting services with any other for-profit entities unless Advisor receives prior written approval from the Board or Senior Management of Company, which
approval shall not be unreasonably conditioned, withheld or delayed. In reviewing any request for approval of a proposed consulting relationship, Company may not require the disclosure of any confidential or proprietary information belonging to the
other entity. Company will approve or deny any request for approval of a prospective consulting relationship between Advisor and another entity within ten (10) days of receipt of such request, and the request will be deemed automatically
approved if it is not denied within that ten (10) day period. Company acknowledges that Advisor has existing obligations to perform consulting services for Metamark Genetics, Eden Therapeutics, Karyopharm Therapeutics or Agios and such
consulting relationships are hereby approved by Company and shall not require any further review and approval by Company under this paragraph so long as such existing services do not materially change in either time commitments or scope. 

4. Compensation. 
 4.1 As compensation for the Advisor’s services hereunder, the Company shall pay Advisor, during the Consulting Period, as follows: 

 

	 	(a)	a consulting fee of $50,000.00, payable in quarterly installments in arrears on the first day of January, April, July and October of each year; and

  

	 	(b)	the lesser of (i) $750 per hour, or (ii) $3,000 per day for services performed during meetings of the SAB (as designated and scheduled by the Company).

 The maximum yearly compensation that will be paid to Advisor is $75,000.00. 

4.2. Reimbursement of Expenses. The Company shall reimburse the Advisor for all reasonable and necessary expenses incurred or paid
by the Advisor in connection with, or related to, the performance of her services under this Agreement. The Advisor shall submit to the Company itemized monthly statements, in a form satisfactory to the Company, of such expenses incurred in the
previous month. The Company shall pay to the Advisor amounts shown on each such statement within thirty (30) days after receipt thereof. Notwithstanding the foregoing, the Advisor shall not incur any expenses in excess of $2,500 in any calendar
quarter without the prior written approval of the Company. 

  
 -2-

 4.3. Benefits. The Advisor shall not be entitled to any benefits, coverages or
privileges, including, without limitation, social security, unemployment, medical or pension payments, made available to employees of the Company. The Advisor acknowledges that the Company will not withhold taxes on any amounts paid to her hereunder
and that Advisor is responsible for all tax withholding, social security, unemployment insurance and other similar payments. 

5. Termination. The Company may, without prejudice to any right or remedy it may have due to any failure of the Advisor to perform
her obligations under this Agreement, terminate the Consultation Period upon thirty (30) days’ prior written notice to the Advisor. The Advisor may, without prejudice to any right or remedy she may have due to any failure of the Company to
perform its obligations under this Agreement, terminate this Agreement and the Consultation Period upon thirty (30) days’ prior written notice to the Company. In the event of an early termination of this Agreement, the Advisor shall be
entitled to payment for services performed and expenses paid or incurred prior to the effective date of termination, subject to the limitation on reimbursement of expenses set forth in Section 4.2. Such payments shall constitute full settlement
of any and all claims of the Advisor of every description against the Company. Notwithstanding the foregoing, the Company may terminate the Consultation Period, effective immediately upon receipt of written notice, if the Advisor breaches or
threatens to breach any provision of Sections 6, 7 or 9. The following provisions shall survive termination of this Agreement: Sections 7, 9 and 14. 
 6. Cooperation. In the performance of her obligations under this Agreement, the Advisor shall use her reasonable best efforts, shall reasonably cooperate with the Company’s personnel, shall
not interfere with the conduct of the Company’s business, and shall observe all rules, regulations and security requirements of the Company concerning the safety of persons and property. The Company shall provide such access to its information
and property as may be reasonably required in order to permit the Advisor to perform her obligations hereunder. 
 7.
Inventions and Proprietary Information. 
 7.1. Inventions. All inventions, discoveries, computer programs, data,
technology, designs, innovations and improvements (whether or not patentable and whether or not copyrightable) (“Inventions”) related to the business of the Company which are made, conceived, reduced to practice, created, written, designed
or developed by the Advisor, solely or jointly with others and whether during normal business hours or otherwise, during the Consultation Period while actively serving as an advisor to the Company, as a member of the Company’s SAB, or
thereafter if resulting directly or indirectly derived from Proprietary Information of the Company (as defined below), shall be the sole property of the Company. By way of clarification, any inventions, discoveries, computer programs, data,
technology, designs, innovations and improvements (whether or not patentable and whether or not copyrightable) made, conceived, reduced to practice, created, written, designed or developed by the Advisor, solely or jointly with others, in the course
of the Advisor’s activities with any third party, including without limitation any hospital, research institution, medical institution or otherwise, and not in the course of her performance of consulting services hereunder and which are not
directly or indirectly derived from Proprietary Information, shall not constitute “Inventions” hereunder. The Advisor hereby assigns to the Company all Inventions and any and all related patents, copyrights, trademarks, trade names, and
other industrial and intellectual property rights and applications therefore, in the United States and elsewhere and appoints any officer of the Company as the Advisor’s duly authorized attorney to execute, file, prosecute and protect the

  
 -3-

 
same before any government agency, court or authority. Upon request of the Company and at the Company’s expense, the Advisor shall execute further assignments, documents and other
instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in the United States and in any
foreign country with respect to any Invention. 
 7.2. Proprietary Information. 

7.2.1. The Advisor acknowledges that her relationship with the Company is one of high trust and confidence and that in the course of her
service to the Company she will have access to and contact with Proprietary Information (as defined in subparagraph 7.2.2. below). The Advisor agrees that she will not, during the Consultation Period or at any time thereafter, disclose to others, or
use for her benefit or the benefit of others, any Proprietary Information. 
 7.2.2. For purposes of this Agreement,
Proprietary Information shall mean all non-public information (whether or not patentable and whether or not copyrightable) owned, possessed or used by the Company, including, without limitation, any Invention, formula, reagents, chemical compounds,
substances, cells or cell lines, organisms and progeny, mutants (including derivatives of the foregoing), vendor information, customer information, apparatus, equipment, trade secret, process, research, report, technical data, know-how, computer
program, software, software documentation, hardware design, technology, marketing or business plan, forecast, unpublished financial statement, budget, license, price, cost and employee list that is communicated to, learned of, developed or otherwise
acquired by the Advisor in the course of her service as an advisor to the Company. 
 7.2.3. Proprietary Information excludes,
and the Advisor’s obligations under this Section 7.2 shall not apply to, any information that (i) is or becomes known to the general public under circumstances involving no breach by the Advisor or others of the terms of this
Section 7.2, (ii) is already known by the Advisor prior to the disclosure by Company, (iii) is learned by the Advisor from a third party authorized to disclose such information, (iv) is independently developed by the Advisor
without use of the Company’s Proprietary Information, (v) is required by law (including statute, rule, regulation, order or other legal compulsion) to be disclosed, (vi) is generally disclosed to third parties by the Company without
restriction on such third parties, or (vii) is approved for release by written authorization of the Chief Executive Officer for the Company. 
 7.2.4. Upon termination of this Agreement or at any other time upon request by the Company, the Advisor shall promptly deliver to the Company all Proprietary Information and all records, files, memoranda,
notes, designs, data, reports, price lists, customer lists, drawings, plans, computer programs, software, software documentation, sketches, laboratory and research notebooks and other documents (and all copies or reproductions of such materials)
that relates to the Proprietary Information. 
 7.2.5. The Advisor represents that her retention as an advisor with the Company
and her performance under this Agreement does not, and shall not, breach any agreement that obligates her to keep in confidence any trade secrets or confidential or proprietary information of her or of any other party or to refrain from competing,
directly or indirectly, with the business of any other party. The Advisor shall not disclose to the Company any trade secrets or confidential or proprietary information of any other party. 

  
 -4-

 7.2.6. The Advisor acknowledges that the Company from time to time may have agreements with
other persons or with the United States Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such
work. The Advisor agrees to be bound by all such obligations and restrictions that are known to her and to take all action necessary to discharge the obligations of the Company under such agreements. 

7.3. Remedies. The Advisor acknowledges that any breach of the provisions of this Section 7 shall result in serious and
irreparable injury to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Advisor agrees, therefore, that, in addition to any other remedy it may have, the Company shall be entitled to enforce the
specific performance of this Agreement by the Advisor and to seek both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving actual damages. 

8. Advisor’s Obligations to Advisor’s Employer. Notwithstanding any of the other terms of this Agreement, and in
exception thereto, the parties to this Agreement acknowledge and agree that Advisor is an employee of The University of Texas MD Anderson Cancer Center and therefore Advisor executes this Agreement subject to the Rules and Regulations of The Board
of Regents of The University of Texas System and all terms and conditions therein that apply to Advisor. Advisor has no right, power or authority to assign or enter into any other agreement with respect to intellectual property, confidential or
other proprietary information owned by the Board of Regents that is inconsistent with these Rules and Regulations. A complete copy of the Rules and Regulations of The Board of Regents of The University of Texas System may be found at
http://www.utsystem.edu/bor/rules/. Additionally, the parties understand and agree that it is Advisor’s responsibility to ensure that the Services provided by Advisor hereunder do not infringe on Advisor’s obligations to
Advisor’s Employer with respect to the Rules and Regulations of the Board of Regents of The University of Texas System. 

9. No Conflict of Interest; Non-Competition Agreement. 
 9.1. The Advisor represents and warrants to the Company that the Advisor currently has no agreement with, nor any other obligation to, any third party that would conflict with the terms of this Agreement,
nor shall the Advisor enter into any such agreement nor incur such an obligation, without the prior written consent of the Company. The Advisor further represents that the performance of the Services will not breach any agreement or obligation with
any third party, including without limitation any obligation to refrain from engaging in activities that may compete with such party. The Advisor understands the confidential nature of the information and materials she will acquire or develop in
performing her services under this Agreement. The Advisor acknowledges that if such information or materials were revealed to competitors of the Company, then such disclosure could cause damage to the Company. Therefore, for the duration of the
Consultation Period and for two (2) years thereafter, the Advisor shall not engage in any activities that would compete with the Company-including, without limitation, founding or otherwise holding an equity interest in any other business
entity working in the field (other than as a shareholder of less than 2% of the stock of a publicly traded corporation, provided that Advisor exercise no operational or strategic 

  
 -5-

 
control over such corporation), becoming employed by, serving as a consultant for, serving as a member of a scientific advisory board (or a comparable organization) for, or acting in any manner
on behalf of any other for-profit enterprise that conducts activities similar to or competes with those of the Company, without first obtaining the written consent of the Company. Notwithstanding the foregoing, nothing contained in this
Section 9 or elsewhere in this Agreement shall interfere with, limit or otherwise adversely affect the Advisor’s freedom or ability to perform her duties and responsibilities for the Advisor’s Employer. The Company agrees not to
unreasonably withhold or delay its consent to activities by the Advisor in areas with respect to which the Company either has no business or in which it does not intend to develop business. 

9.2. During the term of this Agreement and for a period of one (1) year commencing on the expiration or termination (if earlier) of
this Agreement, Advisor will not solicit, entice, persuade or induce any individual who is then, or has been within the preceding six-month period, an employee or consultant of the Company or any of its subsidiaries or affiliates to terminate his or
her employment or consulting relationship with the Company or any of its subsidiaries or affiliates or to become employed by or enter into contractual relations with any other individual or entity, and the Advisor shall not approach any such
employee or consultant for any such purpose or authorize or knowingly approve the taking of any such actions by any other individual or entity. The term “affiliate” shall mean any person or entity that directly, or indirectly, through one
or more intermediaries, is controlled or is controlled by, or is under common control of the Company. 
 9.3 Since a breach of
the provisions of this Section 9 could not adequately be compensated by money damages, the Company shall be entitled, in addition to any other right and remedy available to it, to an injunction restraining such breach or a threatened breach,
and in either case no bond or other security shall be required in connection therewith. Advisor agrees that the provisions of this Section 9 are necessary and reasonable to protect the Company in the conduct of its business. If any restriction
contained in this Section 9 shall be deemed to be invalid, illegal, or unenforceable by reason of the extent, duration, or geographical scope thereof, or otherwise, then the court making such determination shall have the right to reduce such
extent, duration, geographical scope, or other provisions hereof, and in its reduced form such restriction shall then be enforceable in the manner contemplated hereby. 
 9.4 The provisions of this Section 9 shall survive any termination or expiration of this Agreement. 
 10. Notices. All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery or upon deposit in the United States Post Office, by
registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 10 

11. Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine,
feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 
 12.
Entire Agreement. This Agreement sets forth the entire understanding of the parties with respect to the subject matter hereof and supersedes and replaces all prior agreements, arrangements and communications, whether oral or written, with
respect to the subject matter hereof and any and all such prior agreements, arrangements and communications shall be deemed terminated. 

  
 -6-

 13. Amendment. This Agreement may be amended or modified only by a written instrument
executed by the Company and the Advisor. 
 14. Governing Law. This Agreement shall be construed, interpreted and
enforced in accordance with the laws of the Commonwealth of Massachusetts. 
 15. Successors and Assigns. This Agreement
shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business, provided,
however, that the obligations of the Advisor are personal and shall not be assigned by her. 
 16. Compliance with
Policies. The Company recognizes that as an employee of a non-profit entity, the Advisor is responsible for ensuring that any consulting agreement the Advisor enters into with a for-profit entity is not in conflict with the intellectual
property, consulting, conflict-of-interest, and other policies of the Advisor’s Employer. The Advisor represents that she has made all of the required disclosures to the Advisor’s Employer and has obtained all necessary approvals of this
Agreement from the appropriate authorities at the Advisor’s Employer. 
 17. Independent Contractor Status. The
Advisor shall perform all services under this Agreement as an “independent contractor” and not as an employee or agent of the Company. The Advisor is not authorized to assume or create any obligation or responsibility, express or implied,
on behalf of, or in the name of, the Company or to bind the Company in any manner. 
 18. Miscellaneous. 

18.1. No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other
right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. 

18.2. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the
scope or substance of any section of this Agreement. 
 18.3. In the event that any provision of this Agreement shall be
invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

  
 -7-

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set forth above.

  

							
	ADVISOR	 		 	AVEO PHARMACEUTICALS, INC.
				
	 /s/ Lynda Chin
	 		 	By:	 	 /s/ Murray O. Robinson

	Lynda Chin, MD	 		 		 	Murray O. Robinson, PhD
		 		 		 	 Senior Vice President, Translational Research
 Chair of the Scientific Advisory Board

  
 -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]